Eric Shaff, Seres CEO
'By no means are we deterred': Seres' stock spirals after PhII microbiome fail in ulcerative colitis
Almost five years after Seres Therapeutics slammed into a Phase II failure with its lead candidate, the microbiome pioneer is reporting another massive flop …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
